Bedømmelsen af effekten over for invasiv sygdom kommer fra den amerikanske befolkning, hvor vaccine serotype dækningen varierer mellem 80 til 89%.
Estimates of efficacy against invasive disease were obtained in the US population where vaccine serotype coverage ranged from 80 to 89%.